Shots:
The P-III (SENTRY) trial assessed Selinexor (60mg, QW) + ruxolitinib vs PBO + ruxolitinib in 353 pts with frontline myelofibrosis; FDA discussions on SENTRY data & its sNDA strategy is underway, with potential compendia inclusion in H2’26
As of Feb 20, 2026, trial met its first co-1EP, with 50% vs 28% achieving SVR35 at…
